TRANSTHYRETIN AMYLOID CARDIOPATHY
Clinical trials for TRANSTHYRETIN AMYLOID CARDIOPATHY explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOID CARDIOPATHY trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOID CARDIOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising heart drug study pulled before it even started
Disease control TerminatedThis study aimed to see if a new drug, ION-682884, could slow or stop heart damage in people with TTR amyloidosis, a condition where abnormal protein builds up in the heart. Only patients who had already completed a 24-month study of a similar drug (inotersen) were eligible. The …
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOPATHY
Phase: PHASE2 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated May 26, 2026 08:59 UTC
-
New registry to map how ATTR-CM is treated in daily practice
Knowledge-focused OngoingThis study collects information from medical records of about 350 adults with transthyretin amyloid cardiomyopathy (ATTR-CM) in Taiwan, Hong Kong, and Malaysia. Researchers will look at patient characteristics, treatments, and outcomes as part of routine care. No experimental dru…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOPATHY
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated May 26, 2026 08:59 UTC